The Pharmacy Times® Multiple Myeloma Resource Center is a comprehensive resource for clinical news and expert insights on issues related to cancer that forms in a type of white blood cell.
April 21st 2024
Integration of these agents requires supportive care considerations for cytokine release syndrome, neurotoxicity, infection, and antigen-specific toxicities to ensure optimal care of patients with multiple myeloma receiving T-cell–engaging therapies.
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Chronic Myeloid Leukemia: Navigating Drug Resistance and Optimizing Care
1.0 Credit / Hematologic Cancer, Hematology, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care
1.0 Credits / Hematologic Cancer, Oncology
View More
Revolutionizing Multiple Myeloma Care: CAR T-Cell Therapy, Bispecific Antibodies, and Patient-Centered Strategies
1.0 Credit / Oncology, Hematologic Cancer
View More
How Trial Results Assessing Dara-KRd in Multiple Myeloma May Impact the Treatment Landscape
December 24th 2021Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses how the results of the trial assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma may impact the treatment landscape.
Watch
Adverse Events in Trial Assessing Dara-KRd in Patients With Newly Diagnosed Multiple Myeloma
December 23rd 2021Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the adverse events experienced by patients with newly diagnosed multiple myeloma who were administered daratumumab, carfilzomib, lenalidomide, and dexamethasone.
Watch
Assessing Trial Results for All Endpoints for Dara-KRd in Treatment of Multiple Myeloma
December 22nd 2021Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the results for all of the trial endpoints assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone for patients with newly diagnosed multiple myeloma.
Watch
Assessing the Primary Endpoint Trial Results for Dara-KRd in Treatment of Multiple Myeloma
December 21st 2021Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the primary endpoint in the trial assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone in the treatment of patients with newly diagnosed multiple myeloma.
Watch
Safety, Efficacy of Dara-KRd in Treatment of Patients With Newly Diagnosed Multiple Myeloma
December 20th 2021Luciano Costa, MD, PhD, associate director for clinical research at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, on the safety and efficacy of Dara-KRd in the treatment of patients with newly diagnosed multiple myeloma.
Watch
Study: Immune-Boosting Antibody Treatment Isatuximab Meets Primary Endpoint for Multiple Myeloma
December 15th 2021This trial is the first to assess the use of isatuximab as a first-line treatment for newly diagnosed, transplant-eligible patients up to 70 years of age, according to the study authors.
Read More
FDA Approves Daratumumab Triplet Combo for Relapsed/Refractory Multiple Myeloma
December 2nd 2021The combination of daratumumab with hyaluronidase (Darzalex Faspro), hyaluronidase-fihj, carfilzomib (Kyprolis), and dexamethasone is indicated for the treatment of adult patients with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy.
Read More
TAK1-Inhibitors Offer Potential Treatment Strategy for Patients With Multiple Myeloma
October 19th 2021TAK1 restricts receptor-interacting serine/threonine-protein kinase 1 dependent cell death, and targeting TAK1 with inhibitors shifts cells from pro-survival programs to cell death, according to the study.
Read More
The Impact of the FDA's Project Optimus on Oncology Drug Trials
October 1st 2021In an interview with Pharmacy Times®, Maria Whitman, Global Head of the Pharmaceutical and Biotech Practice at ZS, discusses the FDA’s Project Optimus, the FDA’s new guidance addressing dose optimization issues in oncology clinical trials, and how it has impacted drug manufacturers.
Watch
Novel Small Molecule Drugs for the Treatment of Triple-Class Refractory Myeloma
September 29th 2021Robert Z. Orlowski, MD, PhD, director of the Myeloma Section at the University of Texas MD Anderson Cancer Center, reviewed novel agents in the treatment of triple-class refractory myeloma during a session at the 2021 annual meeting of the Society of Hematologic Oncology (SOHO).
Read More